Summary

The level of disease (single or multilevel), the absolute number of involved lymph nodes, the possible presence of bulky disease, and downstaging after induction can all have an impact on outcome and survival of non-small cell lung cancer (NSCLC). This article discusses factors that should be considered prior to surgery for stage III NSCLC, optimal radiotherapy combined with chemotherapy for stage III NSCLC, as well as a review of some of the data and ongoing trials for targeted agents in stage I to III NSCLC.